Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer (ARMOR2)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Tokai Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01709734
First received: October 16, 2012
Last updated: August 31, 2016
Last verified: August 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: August 2017
  Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)